Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study
Posted on 2020-09-19 - 03:31
Abstract Background Optimal prophylactic and therapeutic management of thromboembolic disease in patients with COVID-19 remains a major challenge for clinicians. The aim of this study was to define the incidence of thrombotic and haemorrhagic complications in critically ill patients with COVID-19. In addition, we sought to characterise coagulation profiles using thromboelastography and explore possible biological differences between patients with and without thrombotic complications. Methods We conducted a multicentre retrospective observational study evaluating all the COVID-19 patients received in four intensive care units (ICUs) of four tertiary hospitals in the UK between March 15, 2020, and May 05, 2020. Clinical characteristics, laboratory data, thromboelastography profiles and clinical outcome data were evaluated between patients with and without thrombotic complications. Results A total of 187 patients were included. Their median (interquartile (IQR)) age was 57 (49–64) years and 124 (66.3%) patients were male. Eighty-one (43.3%) patients experienced one or more clinically relevant thrombotic complications, which were mainly pulmonary emboli (n = 42 (22.5%)). Arterial embolic complications were reported in 25 (13.3%) patients. ICU length of stay was longer in patients with thrombotic complications when compared with those without. Fifteen (8.0%) patients experienced haemorrhagic complications, of which nine (4.8%) were classified as major bleeding. Thromboelastography demonstrated a hypercoagulable profile in patients tested but lacked discriminatory value between those with and without thrombotic complications. Patients who experienced thrombotic complications had higher D-dimer, ferritin, troponin and white cell count levels at ICU admission compared with those that did not. Conclusion Critically ill patients with COVID-19 experience high rates of venous and arterial thrombotic complications. The rates of bleeding may be higher than previously reported and re-iterate the need for randomised trials to better understand the risk-benefit ratio of different anticoagulation strategies. Graphical abstract
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Shah, Akshay; Donovan, Killian; McHugh, Anna; Pandey, Manish; Aaron, Louise; Bradbury, Charlotte A.; et al. (2020). Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.5126945.v1
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (20)
AS
Akshay Shah
KD
Killian Donovan
AM
Anna McHugh
MP
Manish Pandey
LA
Louise Aaron
CB
Charlotte A. Bradbury
SS
Simon J. Stanworth
RA
Raza Alikhan
SV
Stephen Von Kier
KM
Keith Maher
NC
Nicola Curry
SS
Susan Shapiro
MR
Matthew J. Rowland
MT
Matt Thomas
RM
Richard Mason
MH
Matthew Holland
TH
Tom Holmes
MW
Michael Ware
SG
Stefan Gurney
SM
Stuart R. McKechnie